Novartis Chief Executive Vas Narasimhan said he will be ready to discuss the future of generics unit Sandoz following a revamp due to take 18 months, while still calling the business "an integral part" of the Swiss drugmaker.
诺华首席执行官 VasNarasimhan 说，他将准备讨论仿制药部门 Sandoz 的未来，因为改造将需要18个月，同时仍然称该业务是瑞士制药商的一个组成部分。
"We consider Sandoz an integral part of Novartis, we're focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis," Narasimhan said on a call with analysts on Wednesday. "After we complete all that, then I think we can have further conversations about where we want to head from there."
Narasimhan 周三在与分析师的电话会议上表示：“我们认为 Sandoz 是诺华的一个组成部分，我们专注于转型业务，使其在未来18个月成为一个独立的实体，能够作为诺华的一个独立部门进行竞争。”“在我们完成所有这些之后，我认为我们可以进一步讨论我们想从那里出发的地方。”
In November, Novartis said it was "completely committed" to the $10 billion-per-year generics business despite price pressure that prompted the sale of its U.S pills business, after a newspaper reported Narasimhan planned to eventually split the unit off.
去年11月，诺华表示，尽管价格压力促使其美国市场销售，但它“完全致力于”每年100亿美元的仿制药业务。在一家报纸报道 Narasimhan 计划最终拆分该部门后， 仿制药 药片业务开始了。
本文未完，阅读全文请访问www.investank.com
